---
title: "Invicta Diagnostic Ltd (INVICTA) — Share Price, Financials & Analysis"
symbol: "INVICTA"
company: "Invicta Diagnostic Ltd"
canonical: "https://tapetide.com/stocks/INVICTA"
isin: "INE0XJ501010"
nse_symbol: "INVICTA"
sector: "Healthcare Services"
industry: "Healthcare Service Provider"
market_cap_cr: 87.44
generated_at: "2026-09-13T18:59:14.013Z"
---

# Invicta Diagnostic Ltd (INVICTA)

Canonical page: https://tapetide.com/stocks/INVICTA

## Company

- **NSE Symbol:** INVICTA
- **ISIN:** INE0XJ501010
- **Sector:** Healthcare Services
- **Industry:** Healthcare Service Provider
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2025-12-08
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** pcdiagnostics.in

## About

Incorporated in January 2021, Invicta Diagnostic Limited offers radiology and pathology solutions [1]

## Latest Price

- **Price:** ₹68
- **Change:** -1 (-1.45%)
- **Open:** ₹69.55
- **Day High:** ₹69.55
- **Day Low:** ₹68
- **Previous Close:** ₹69
- **Volume:** 3200
- **As Of:** 2026-09-11T08:25:30+00:00

## Key Fundamentals

Observed at 2026-09-11T04:49:01.233381Z.

- **Market Cap:** ₹87.44 Cr
- **Classification:** SME
- **P/E (reported):** 17.8
- **Book Value:** ₹39.71
- **Price to Book:** 1.74
- **Dividend Yield:** 0%
- **ROE:** 9.76%
- **ROCE:** 13.57%
- **Debt to Equity:** 0.07
- **Revenue (yearly):** ₹33 Cr
- **Net Income:** ₹4.9 Cr
- **EBITDA:** ₹10.5 Cr
- **52-Week High:** ₹105
- **52-Week Low:** ₹58.1
- **RSI (14):** 48.07

## Key Insights

### Strengths

- Company is almost debt free.

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| cash flow growth | -55.34% | -30.4% | 240.7% |
| ebitda margin growth | 2.83% | -29.68% | — |
| net income growth | 0% | 37% | — |
| revenue growth | 9.27% | 63% | — |
| roce | -63.01% | -33.35% | — |
| roe | -73.08% | 23.38% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2025 | Mar 2026 |
| --- | --- | --- |
| Sales | 16.95 | 15.41 |
| Expenses | 10.19 | 12.42 |
| Operating Profit | 6.76 | 2.99 |
| OPM % | 39.88 | 19.4 |
| Other Income | 0.13 | 0.56 |
| Interest | 0.1 | 0.09 |
| Depreciation | 1.37 | 1.88 |
| Profit before tax | 5.42 | 1.58 |
| Tax % | 24.72 | 50 |
| Net Profit | 4.08 | 0.79 |
| EPS in Rs | 4.32 | 0.72 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Sales | 7.46 | 7.99 | 30.1 | 32.35 |
| Expenses | 4.22 | 4.59 | 20.91 | 22.58 |
| Operating Profit | 3.24 | 3.4 | 9.19 | 9.77 |
| OPM % | 43.43 | 42.55 | 30.53 | 30.2 |
| Other Income | 0 | 0.35 | 0.09 | 0.69 |
| Interest | 0.02 | 0.08 | 0.23 | 0.2 |
| Depreciation | 0.95 | 0.98 | 2.49 | 3.25 |
| Profit before tax | 2.27 | 2.69 | 6.56 | 7.01 |
| Tax % | 22.91 | 0 | 25 | 30.39 |
| Net Profit | 1.76 | 2.69 | 4.93 | 4.88 |
| EPS in Rs | — | 204.56 | 5.81 | 3.91 |
| Dividend Payout % | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Equity Capital | — | 0.13 | 8.42 | 12.57 |
| Reserves | — | 12.05 | 5.18 | 37.35 |
| Borrowings | — | 1.87 | 3.53 | 3.67 |
| Other Liabilities | — | 1.79 | 4.09 | 6.65 |
| Total Liabilities | — | 15.84 | 21.22 | 60.24 |
| Fixed Assets | — | 11.78 | 9.58 | 19.2 |
| CWIP | — | 0 | 0 | 0 |
| Investments | — | 0 | 4.33 | 6.2 |
| Other Assets | — | 4.06 | 7.31 | 34.84 |
| Total Assets | — | 15.84 | 21.22 | 60.24 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Cash from Operating Activity | — | 4.21 | 6.56 | 2.93 |
| Cash from Investing Activity | — | -10.01 | -5.23 | -13.67 |
| Cash from Financing Activity | — | 7.14 | -0.5 | 30.79 |
| Net Cash Flow | — | 1.34 | 0.83 | 20.05 |
| Free Cash Flow | — | -8.56 | 6.23 | -9.93 |
| CFO/OP | — | 124 | 71 | 40 |

### Ratios

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Debtor Days | — | 37.46 | 17.7 | 6.43 |
| Inventory Days | — | 296.56 | 83.33 | 78.88 |
| Days Payable | — | 1102.6 | 70 | 254.03 |
| Cash Conversion Cycle | — | -768.58 | 31.04 | -168.72 |
| Working Capital Days | — | 5.94 | 18.55 | 55.74 |
| ROCE % | — | — | 45.04 | 19.43 |

## Shareholding Pattern

### Quarterly

| Category | Dec 2025 | Mar 2026 |
| --- | --- | --- |
| Promoters | 66.7% | 66.7% |
| FIIs | 0.94% | 4.2% |
| DIIs | 10.22% | 4.3% |
| Government | 0% | 0% |
| Public | 18.49% | 18.71% |
| Others | 3.66% | 6.1% |
| No. of Shareholders | 34 | 411 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 0 / 9 / 10

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 68.53 | Sell |
| EMA (10) | 68.63 | Sell |
| SMA (20) | 69.76 | Sell |
| EMA (20) | 69.31 | Sell |
| SMA (50) | 69.56 | Sell |
| EMA (50) | 70 | Sell |
| SMA (100) | 72.73 | Sell |
| EMA (100) | 71.5 | Sell |
| SMA (200) | — | Neutral |
| EMA (200) | — | Neutral |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 45.33 | Neutral |
| MACD (12,26,9) | -0.69 | Sell |
| Stochastic (14,3,3) | 29.91 | Neutral |
| ADX (14) | 20.06 | Neutral |
| Williams %R (14) | -74.36 | Neutral |
| ATR (14) | 2.44 | High Volatility |
| ROC (12) | -2.86 | Sell |
| Stoch RSI (14) | 35.05 | Neutral |
| UO (7,14,28) | 37.74 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 8 May 2026 - Invicta Diagnostic acquired 51% stake in Vinchurkar Diagnostics on 8 May 2026. | [Acquisition 8 May 2026 - Invicta Diagnostic acquired 51% stake in Vinchurkar Diagnostics on 8 May 2026.](https://nsearchives.nseindia.com/corporate/INVICTA_08052026194848_Regulation_30_Restructuring_INVICTA_08052026.pdf) |
| 31 March 2026 - Trading window closed from April 1, 2026 until 48 hours after audited FY/HY results for year ended March 31, 2026. | [Trading Window 31 March 2026 - Trading window closed from April 1, 2026 until 48 hours after audited FY/HY results for year ended March 31, 2026.](https://nsearchives.nseindia.com/corporate/INVICTA_31032026140400_Invicta_TWC_31032026.pdf) |
| 30 June 2026 - Pune diagnostic centre of subsidiary Porteus Medical LLP began operations on 30 June 2026; ₹416 lakh investment. | [Commencement of commercial production/operations 30 June 2026 - Pune diagnostic centre of subsidiary Porteus Medical LLP began operations on 30 June 2026; ₹416 lakh investment.](https://nsearchives.nseindia.com/corporate/INVICTA_30062026190606_Intimation_Pune_Centre_30062026.pdf) |
| 30 January 2026 - Primacare started commercial operations at Dadar Centre on 30 Jan 2026; ₹550 lakh investment; PET-CT, CT, pathology services. | [Commencement of commercial production/operations 30 January 2026 - Primacare started commercial operations at Dadar Centre on 30 Jan 2026; ₹550 lakh investment; PET-CT, CT, pathology services.](https://nsearchives.nseindia.com/corporate/INVICTA_30012026201428_Intimation_Dadar_30012026.pdf) |
| 29 May 2026 - Invicta Diagnostic reported no deviation in IPO fund use for half year and year ended March 31, 2026. | [Statement of deviation(s) or variation(s) under Reg. 32 29 May 2026 - Invicta Diagnostic reported no deviation in IPO fund use for half year and year ended March 31, 2026.](https://nsearchives.nseindia.com/corporate/INVICTA_29052026124801_Statementofdeviation_31032026.pdf) |
| 29 Jul - On 29 July 2026, Invicta appointed Sanket Jain Managing Director and accepted two resignations. | [Outcome of Board Meeting 29 Jul - On 29 July 2026, Invicta appointed Sanket Jain Managing Director and accepted two resignations.](https://nsearchives.nseindia.com/corporate/INVICTA_29072026175718_Outcome_BM_29072026.pdf) |
| 29 Jul - Invicta Diagnostic Limited has informed about Resignation of Director/KMP/SMP | [Resignation of Director/KMP/SMP 29 Jul - Invicta Diagnostic Limited has informed about Resignation of Director/KMP/SMP](https://nsearchives.nseindia.com/corporate/INVICTA_ROID_93472_KMP_Doc.zip) |
| 28 January 2026 - Three diagnostic LLPs incorporated (Shegaon 20-Jan-2026; two Mumbai 16-Jan-2026); contributions ₹51,000, ₹99,000, ₹99,000. | [Acquisition 28 January 2026 - Three diagnostic LLPs incorporated (Shegaon 20-Jan-2026; two Mumbai 16-Jan-2026); contributions ₹51,000, ₹99,000, ₹99,000.](https://nsearchives.nseindia.com/corporate/INVICTA_28012026151100_Intimation_28012026_LLPIncorporation.pdf) |
| 28 January 2026 - Invicta incorporated three diagnostic LLPs Jan 16–28, 2026; subscribed cash capital ₹51,000, ₹99,000, ₹99,000. | [Acquisition 28 January 2026 - Invicta incorporated three diagnostic LLPs Jan 16–28, 2026; subscribed cash capital ₹51,000, ₹99,000, ₹99,000.](https://nsearchives.nseindia.com/corporate/INVICTA_28012026151944_Intimation_28012026_LLPIncorporation1.pdf) |
| 27 February 2026 - Completed sale of 9% stake in Primacare Diagnostic LLP for Rs.9,000 on Feb 27, 2026. | [Sale or disposal 27 February 2026 - Completed sale of 9% stake in Primacare Diagnostic LLP for Rs.9,000 on Feb 27, 2026.](https://nsearchives.nseindia.com/corporate/INVICTA_27022026185526_Intimation_Sale_PD.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_30610_INVICTA_2025_2026_A_13001782_25082026182300.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:59:14.013Z.